SEC Filings

SEC FILINGS

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807

Tel: 1-908-955-3140
Mail: info@hillstreambio.com

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule February 15, 2023
Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer February 13, 2023
In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer February 10, 2023